Navigation Links
Synedgen Announces Effective Treatment Against Bacterial Biofilms in Minor Animal Species
Date:5/5/2013

Claremont CA (PRWEB) May 05, 2013

Removing embedded bacteria from biofilms in wounds remains a challenge to doctors and caregivers. Likewise, veterinarians face similar challenges treating their zoo patients. Synedgen will report compelling data on new treatments against wound biofilms at a poster session at the 113th General Meeting of the American Society for Microbiology (asm2013) on May 18-21, 2013, at the Colorado Convention Center in Denver Colorado.

The poster, Antibacterial and Wound Healing Enhancement of PAAG in Minor Species, highlights the antibacterial and biofilm-reducing activity of Synedgen’s Synoplex® rinse. Data will be presented for efficacy against bacteria from elephant wounds and for Klebsiella pneumoniae biofilms. Data from additional collaborative studies evaluating Synoplex in the treatment of chronic elephant and rhinoceros wounds, including foot-disease, pressure ulcers, and infected glands that were not responding well to conventional treatment will also be presented. Synoplex is approved for marketing by the FDA as a treatment for wounds in elephants and rhinoceros.

Bacteria isolated from elephant wounds were all reduced more than 1000 fold after 1-hour treatment with Synoplex. K. pneumonia biofilms were reduced by more than 1000 fold after 5-hour treatment. Epithelial cells, which are responsible for the initial stages of regeneration of tissue, grew to cover at least twice more surface area than other wound treatments and control. Treated minor species showed significant improvement in wound healing and successful resolution of most wounds.
Synedgen’s VP of Research Stacy Townsend PhD will present the results on Tuesday May 21, 2013 at 1:00 PM - 2:45 PM at Poster board # 2194.

“As demonstrated by these studies, Synoplex provides a highly effective prophylactic and therapeutic treatment for controlling and preventing bacterial biofilms associated with chronic and acute dermal wounds including foot disease in minor species,” remarked Townsend. “The non-toxic nature of Synoplex is also beneficial in a large animal setting.”

Synoplex is available directly from Synedgen. For pricing and ordering information, please contact Synedgen at info(at)synedgen(dot)com.

About Synedgen

Synedgen Inc. is an innovative biopharmaceutical company focused on developing novel therapies and products through its proprietary biomaterials technology platform. Product development is targeted to specifically address unmet needs for therapies to treat inflammation, damage or infection at dermal, pulmonary and gastrointestinal surfaces.

Synedgen’s Corporate Headquarters, Research Laboratories and Manufacturing Facility are in Claremont CA. Additional information can be found at Synedgen’s web site at http://www.synedgen.com.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10700553.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Synedgen Announces Issuance of Patent to Optimize Animal Health
2. Synedgen’s Synoplex® Receives FDA Indexing for Use in the Treatment of Chronic Wounds in Pachyderms
3. Small Business Online SEO Class Enrolling Now, Announces JM Internet
4. Anthera Announces First Quarter 2013 Financial Report and Conference Call
5. Life Technologies Announces First Quarter 2013 Results
6. ETEX Corporation announces extended Supply Agreement with Knee Creations, LLC
7. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
8. BioLife Solutions Announces License Agreement
9. PRIM&R Announces Longtime Leader to Step Down
10. MiMedx Announces Record First Quarter 2013 Results
11. ViroPharma Announces First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- A person commits a crime, and the detective uses ... criminal down. An outbreak of foodborne illness makes ... uses DNA evidence to track down the bacteria that caused ... not. The FDA has increasingly used a complex, cutting-edge technology ... Put as simply as possible, whole genome sequencing is a ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... today announced the launch of the Supplyframe Design Lab . Located in ... to explore the future of how hardware projects are designed, built and brought ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:6/9/2016)... leader in attendance control systems is proud to announce the introduction of fingerprint attendance ... the right employees are actually signing in, and to even control the opening of ... ... ... Photo - ...
(Date:6/2/2016)... , June 2, 2016 The ... has awarded the 44 million US Dollar project, for ... Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... leader in the production and implementation of Identity Management Solutions. ... January, however Decatur was selected for ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
Breaking Biology News(10 mins):